Global Sepsis Diagnostics Market valued at USD 510 million (2021), is set to witness a healthy growth of 9% in the upcoming 5 years
Sepsis is a life-threatening medical emergency. It is
body's reaction to infection that may lead to a systemic inflammatory reaction,
tissue damage, and ultimately organ dysfunction and/or failure.
As per WHO, globally, sepsis affects around 49
million people each year. Early diagnosis of sepsis is critical for patient
outcomes. However, diagnosing sepsis is not an easy task as there is no
particular symptom or sign that are directly related to the disease.
Development
of Rapid Diagnostic Tests/Point-of-Care Techniques Set to Drive the Sepsis
Diagnostics Market
Currently, clinicians possess
limited technology needed to conduct multiplexed and fully quantitative
diagnostic tests at the point of care with high sensitivity. Citing the need
for rapid diagnostic tests, several research universities and product
manufacturers are developing innovative rapid diagnostic tests/point-of-care
techniques.
For instance,
- Researchers at the University of Strathclyde have developed an innovative, low cost test for early diagnosis of sepsis. The experimental device analyzes patient's blood and provides results in just 2.5 minutes compared to current testing methods for sepsis which takes up to 72 hours.
“With sepsis, timing is the key. Advancements in diagnostic
speed, range, and accuracy are critical for addressing the continued rise in
sepsis cases and deaths. Advent of new rapid diagnostic tests for sepsis can
save thousands of lives.” - Senior Director, Leading
In-Vitro Diagnostics Manufacturer, USA
Get Customized Report on Sepsis Diagnostics Market @ https://meditechinsights.com/sepsis-diagnostics-market/
Favorable Initiatives
& Funding for Sepsis Research
In an endeavor to shape the future of sepsis
research, (NIGMS)
intends to use the NIH SBIR/STTR program to support preclinical and clinical
sepsis studies to develop improved diagnostic tools and therapies.
Diagnostics companies are also continuously
securing funding to develop rapid sepsis diagnostic tests.
For instance,
- In
February 2022, CytoVal, a medical diagnostics company secured additional
funding from Biomedical Advanced Research and Development Authority (BARDA) to
help advance the company’s 10-minute IntelliSep™ sepsis risk stratification
test towards commercial launch.
- In
June 2021, HelixBind secured $3 million National Institutes of Health (NIH)
grant to support testing of its rapid diagnostic platform for invasive
infections associated with sepsis.
Competitive Landscape Analysis: Sepsis Diagnostics Market
The Sepsis Diagnostics market is marked by presence of both established
players such as bioMérieux, Becton, Dickinson and Company, Thermo Fisher
Scientific, Danaher Corporation and innovative firms such as Seegene Inc.,
Axis-Shield Diagnostics, Immunexpress, and others.
For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/
Comments
Post a Comment